Medication info

Ritagen Duo Tablet 2.5/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Albozen Korea Co., Ltd.
Appearance
Bright yellow, oval-shaped, biconvex film-coated tablet
Packaging
30 tablets/bottle, 30 tablets/PPT [10 tablets/PTPx3]
Approval status
Approval withdrawn

MFDS item code 202106091 · Approved 2021.08.23

This product's status changed to Approval withdrawn on 2024.01.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be made gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes mellitus may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Albozen Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in controlling blood sugar
View approved original text

This medication is used to help control blood sugar levels in adults with type 2 diabetes. It assists in improving blood glucose levels while supporting dietary and exercise interventions. It is administered in cases where there has been no prior experience with diabetes medication treatment or when blood sugar control is difficult with monotherapy alone. It can also serve as an alternative to the combination therapy of Linagliptin and Metformin. When insulin and Metformin combination therapy does not provide adequate control, this medication is used in conjunction with insulin. If there is insufficient effect even with the maximum dosage of Metformin and Empagliflozin combined, this medication is administered alongside Empagliflozin to enhance blood glucose control. It is used in various cases to improve blood sugar regulation.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, dose increases should be made gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes mellitus may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication may cause serious side effects such as lactic acidosis due to its Metformin Hydrochloride component, and there have been reported fatalities. It should not be administered to certain patients, such as those allergic to the active ingredients, or those with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. Additionally, it should not be given to patients with severe renal impairment, severe liver dysfunction, acute infections or dehydration, or acute diseases such as acute myocardial infarction. Pregnant or breastfeeding women are also advised against using this medication. There is a possibility of hypoglycemia; therefore, special caution should be taken when used with insulin or sulfonylureas, and dosages of other medications may need to be adjusted as necessary. Patients with reduced renal function should assess their kidney function prior to using this medication and undergo regular kidney function tests. Serious pancreatic diseases, such as acute pancreatitis, may occur; therefore, if severe abdominal pain develops during use, immediate consultation with a physician is necessary. This medication may reduce vitamin B12 levels, so it is essential to regularly check for vitamin B12 deficiency during long-term use. Furthermore, this drug may interact with other medications; thus, it is crucial to inform the doctor or pharmacist of any current medications being taken. If planning to become pregnant or if already pregnant, it is advised to avoid using this medication and to consider alternative methods such as insulin treatment for blood glucose management. Elderly patients may have a higher risk of reduced kidney function; therefore, starting at the lowest possible dose and monitoring kidney function regularly is necessary for effective blood glucose management. It is important to consult healthcare professionals immediately if any unusual symptoms or side effects occur during use.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorders
  • cough
  • reduced appetite
Show 123 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • reduced appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • anemia
  • dizziness
  • sensory loss
  • chest discomfort
  • myasthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • vocal disorders
  • allergic rhinitis
  • exertional dyspnea
  • productive cough
  • runny nose
  • lung mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • androgenetic alopecia
  • hyperhidrosis
  • dermatitis
  • anxiety
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This helps to preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bright yellow, oval-shaped, biconvex film-coated tablet

Package unit

30 tablets/bottle, 30 tablets/PPT [10 tablets/PTPx3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.